Try GOLD - Free
The Ministry of Everything
Business Standard
|October 17, 2025
India’s pharma regulatory failures point to a deeper structural flaw
The recent tragedy of the contaminated cough syrups, leading to heartbreaking and avoidable deaths of children both here and abroad is not an isolated incident. It is merely the latest, most horrific symptom in a continuing and distressingly predictable series of regulatory failures that plague India’s health sector. When one drills down, the pathology is not just in the failed product or the rogue manufacturer; it’s lodged deep in the very design of the regulatory machinery intended to protect the public.
The systemic rot is visible across the landscape. The cough syrup disaster, which indicts the Central Drugs Standard Control Organisation (CDSCO) and its state-level counterparts, finds an echo in other critical areas. We have seen similar, recurrent lapses in the regulation of food articles, where the Food Safety and Standards Authority of India (FSSAI) often seems overwhelmed. We have also seen this in the oversight of hospital and medical establishments, where quality-of-care issues remain largely unchecked.
These are not independent, random occurrences. They are all pointers to a larger, more fundamental issue. When we look at pharma, food, or clinical establishments, it is natural and logical for us to focus on the regulatory agency. But the sad truth is that the regulators in these three domains, and indeed most regulatory agencies of the Ministry of Health and Family Welfare (MoHFW), suffer from basic design flaws.
What do we mean by this?
This story is from the October 17, 2025 edition of Business Standard.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Business Standard
Business Standard
‘Investor awareness becomes more important than ever’
Ananth Narayan G describes his three-year tenure as whole-time member of the Securities and Exchange Board of India (Sebi) as a privilege that allowed him to make an impact on a larger canvas.
3 mins
November 01, 2025
Business Standard
New currency of hard power
If China is an exporting superpower, America is an importing one. Mr Trump has turned what would usually be a liability into an asset
5 mins
November 01, 2025
Business Standard
Apple's India revenue hits new high in Sep qtr
Apple set an all-time revenue record in India for the September quarter, driven by strong iPhone sales, as the American technology giant’s overall sales revenue reached $102.5 billion globally.
1 mins
November 01, 2025
Business Standard
USFDA's new biosimilar norms to woo more players, fast-track mkt entry
The US Food and Drug Administration’s (USEDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars — lower-priced, near-replicas of complex biologic medicines — could significantly benefit Indian biotech companies.
2 mins
November 01, 2025
Business Standard
Apple revenue tops $100 bn for first time
iPhone price hike drives record quarter
1 mins
November 01, 2025
Business Standard
Broking industry sees high growth on digital push
The Indian broking industry is passing through a lean patch after two years of rapid growth and expansion.
3 mins
November 01, 2025
Business Standard
Al-related stocks have more room to grow'
Artificial intelligence (AI)-related stocks have more room to grow, said Mark Matthews, managing director (MD) and head of research for Asia at Julius Baer during lunch on the sidelines of the Business Standard BFSI Insight Summit 2025 on Friday.
1 mins
November 01, 2025
Business Standard
'Al unlikely to replace humans in fin services'
Artificial intelligence, or AI, has had an influence in the way we invest in stocks. While it helps you narrow the list of opportunities, it has not reached a point where it can replace wealth managers, points out Shankar Sharma, founder, GQuants, in a fireside chat with A K Bhattacharya. Edited excerpts:
4 mins
November 01, 2025
Business Standard
Vedanta net profit plunges 59% on exceptional losses
Mining major Vedanta’s consolidated net profit plunged 58.69 per cent year-on-year (Y-0-Y) to %1,798 crore inthe second quarter of 2025-26 (Q2FY26), dragged down by exceptional losses booked during the period under review. The company had reported anet exceptional gain of $1,160 crore in Q2FY25.
2 mins
November 01, 2025
Business Standard
Sebi chief stresses responsible tech use, stronger market resilience
The Securities and Exchange Board of India (Sebi) is promoting the responsible use of emerging technologies, such as artificial intelligence in financial markets, strengthening cybersecurity, and preparing entities for change, said Chairman Tuhin Kanta Pandey on Friday.
1 mins
November 01, 2025
Listen
Translate
Change font size
